Effect of Probiotic on Gut Microbiota in Young Children With Functional Constipation

Overview

This study was a 28-day, open-label, randomized controlled trial involving infants and toddlers diagnosed with functional constipation. Participants were randomized to receive either Bifidobacterium longum subsp. longum Dipro-X, lactulose, or a combination of both. The primary clinical outcomes assessed were bowel movement frequency, stool consistency, and defecation difficulty. To investigate potential mechanisms, stool samples were collected pre- and post-intervention for metagenomics sequencing to analyze changes in gut microbiota composition and identify specific bacterial taxa associated with clinical improvements.

Functional constipation is a prevalent chronic gastrointestinal disorder with significant implications for pediatric health. Within the first year of life, many infants are affected, a figure that rises to over 10% annually. This condition not only diminishes the quality of life for infants and toddlers but also contributes to substantial healthcare costs. Early intervention is widely recognized as critical for improving treatment outcomes, underscoring the need for effective therapeutic strategies. Growing evidence indicates that intestinal microbiota dysbiosis plays a key role in the pathogenesis of functional constipation. Studies have consistently reported reduced abundances of beneficial bacteria such as Lactobacillus and Bifidobacterium in affected individuals compared to healthy controls. These findings have spurred interest in microbiota-targeted interventions, particularly the use of Bifidobacterium, for managing constipation. Although current evidence-based guidelines do not uniformly recommend probiotics for infant constipation due to limited clinical data, their potential to restore microbial balance remains promising. Advances in genomic technologies have enabled more detailed investigations into strain-specific mechanisms, shifts in signature microorganisms, and associated symptomatic improvements, findings that may help bridge existing evidence gaps. While preclinical studies, such as those involving murine models, have shown that Bifidobacterium longum can alleviate constipation by enhancing intestinal barrier function, clinical evidence in pediatric populations remains scarce. To address this, the present study was conducted as a randomized, open-label, three-arm controlled clinical trial. It aimed to evaluate the efficacy of Bifidobacterium longum subsp. longum Dipro-X, lactulose, and their combination in infants and toddlers with functional constipation. The study specifically assessed the intervention's effects on clinical symptoms, including defecation frequency and stool characteristics, and explored correlations between gut microbiota changes and symptom improvement. The results are intended to support the development of evidence-based, targeted microbial interventions for functional constipation in early childhood.